Nephritis News and Research

RSS

Nephritis is the general term used to describe inflammation of the glomerulus, tubules or interstitial tissue in the kidneys. The condition affects functioning of the kidney and its ability to filter blood and excrete waste products via the urine.

CNDA approves KEYTRUDA for treatment of advanced melanoma

Merck, known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck's anti-PD-1 therapy, has been approved by the China National Drug Administration for the treatment of adult patients with unresectable or metastatic melanoma following failure of one prior line of therapy.

26 Jul 2018

Omeros’ OMS721 receives positive opinion from EMA's COMP for treating hematopoietic stem cell transplant

Omeros Corporation announced today that the European Medicines Agency's Committee for Orphan Medicinal Products issued a positive opinion recommending orphan drug designation of OMS721 for treatment in hematopoietic stem cell transplantation.

25 Jul 2018

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Merck, known as MSD outside the United States and Canada, announced today that the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma, met a primary endpoint of overall survival as monotherapy in patients whose tumors expressed PD-L1.

25 Jul 2018

Aurinia’s Phase 2 trial evaluates voclosporin ophthalmic solution for treating dry eye syndrome

Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company focused on the global immunology market, today announced the initiation of its Phase 2 trial evaluating voclosporin ophthalmic solution (VOS) for the treatment of dry eye syndrome (DES).

12 Jul 2018

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has accepted for standard review a new supplemental Biologics License Application for KEYTRUDA, Merck's anti-PD-1 therapy, as adjuvant therapy in the treatment of patients with resected, high-risk stage III melanoma and granted a Prescription Drug User Fee Act, or target action, date of February 16, 2019.

25 Jun 2018

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

Bristol-Myers Squibb Company today announced patient-reported outcomes data from the Phase 3 CheckMate -214 trial in intermediate- and poor-risk patients with advanced renal cell carcinoma treated with the Immuno-Oncology combination Opdivo plus low-dose Yervoy versus sunitinib over a two-year follow-up period.

1 Jun 2018

Celgene to share new and updated data around novel hematological therapies

Celgene Corporation today announced that data from a broad range of early and late stage studies evaluating Celgene investigational agents and investigational uses of marketed products will be presented at the 23rd European Hematology Association annual meeting in Stockholm, Sweden, from June 14-17, 2018.

22 May 2018

FDA approves first treatment to reduce risk of NSCLC progression

The U.S. Food and Drug Administration today approved Imfinzi (durvalumab) for the treatment of patients with stage III non-small cell lung cancer (NSCLC) whose tumors are not able to be surgically removed (unresectable) and whose cancer has not progressed after treatment with chemotherapy and radiation (chemoradiation).

18 Feb 2018

Vitamin D insufficiency associated with higher rates of renal disease in lupus patients

Low levels of vitamin D were associated with higher rates of end-stage renal disease in patients with systemic lupus erythematosus, or lupus, according to new research findings presented this week at the 2017 ACR/ARHP Annual Meeting in San Diego.

6 Nov 2017

UH professors developing new home test kit for kidney nephritis

With a four-year $1.4 million grant from the National Institutes of Health, two University of Houston engineering professors are developing a home test kit for kidney nephritis, or inflammation, in patients who have Systemic Lupus Erythematosus.

25 Oct 2017

New guideline on care of adults with lupus published

A University of Birmingham academic has led the authorship of the UK's first guideline on the care of adults with systemic lupus erythematosus (lupus).

11 Oct 2017

Researchers discover that beneficial bacteria in yogurt may affect severity of lupus

Researchers at the Virginia-Maryland College of Veterinary Medicine at Virginia Tech have released findings that explain how a type of healthy bacteria in yogurt and other dairy products might reduce disease symptoms in certain patients with lupus.

3 Oct 2017

First-ever treatment for Merkel cell carcinoma receives approval in Japan

Merck KGaA, Darmstadt, Germany, and Pfizer Inc. today announced that the Japanese Ministry of Health, Labor, and Welfare (MHLW) has approved BAVENCIO (avelumab, genetically recombinant Injection 200mg/mL for intravenous use) as the first and only treatment indicated for curatively unresectable Merkel cell carcinoma (MCC), a rare and aggressive cancer, in Japan.

27 Sep 2017

Omeros’ OMS721 receives orphan drug designation from FDA for treatment of IgA nephropathy

Omeros Corporation today announced that OMS721 has received orphan drug designation from the U.S. Food and Drug Administration for the treatment of Immunoglobulin A (IgA) nephropathy.

4 Aug 2017

FDA grants accelerated approval to cancer treatment based on common biomarker

The U.S. Food and Drug Administration today granted accelerated approval to a treatment for patients whose cancers have a specific genetic feature (biomarker).

23 May 2017

FDA grants accelerated approval to new drug for treatment of rare form of skin cancer

The U.S. Food and Drug Administration today granted accelerated approval to Bavencio (avelumab) for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC), including those who have not received prior chemotherapy.

23 Mar 2017

New drug-like compound shows potential to treat symptoms of lupus

Lupus, a chronic autoimmune disease, has proved difficult to treat, but a new international study co-led by a Rush University Medical Center researcher suggests that a drug starting through the pipeline could ameliorate or even eliminate the symptoms in most sufferers.

7 Mar 2017

Results of high-impact clinical trials could improve kidney-related medical care

The results of numerous high-impact clinical trials that could affect kidney-related medical care will be presented at ASN Kidney Week 2016, November 15-20 at McCormick Place in Chicago, IL.

21 Nov 2016

Novel biomarkers enhance power to predict therapeutic efficacy in LN prognostic models

Results of preclinical studies by investigators at the Medical University of South Carolina reported in the August 2016 issue of Arthritis & Rheumatology demonstrate for the first time that including novel biomarkers in lupus nephritis (LN) prognostic models significantly increases their power to predict therapeutic efficacy.

12 Oct 2016

Penicillin allergy testing: an interview with Dr. Eric Macy

Penicillin was one of the first antibiotics developed and has saved millions of lives. First used in the early 1940s, penicillin is still one of the most widely used and least toxic family of antibiotics.

17 Aug 2016